Key result
Meta-analysis identifies ~3,284 differentially expressed genes between MASLD and MASH, revealing novel progression drivers.
Why the study?
The molecular mechanisms underlying the development and progression of MASLD and MASH are not fully understood despite their widespread prevalence and risks of severe liver disease.
Meta-Analysis (n=1,058)
This comprehensive transcriptomic meta-analysis identifies distinct hepatic gene expression signatures and novel key driver genes associated with the progression from normal liver to MASLD and MASH.
This is the authors' abstract. We don't add key points for this paper.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), pose significant risks of severe fibrosis, cirrhosis, and hepatocellular carcinoma. Despite their widespread prevalence, the molecular mechanisms underlying the development and progression of these common chronic hepatic conditions are not fully understood. Here, we conducted the most extensive meta-analysis of hepatic gene expression datasets from liver biopsy samples to date, integrating 10 RNA-sequencing and microarray datasets (1,058 samples). Using a random-effects meta-analysis model, we compared over 12,000 shared genes across datasets. We identified 685 genes differentially expressed in MASLD versus normal liver, 1,870 in MASH versus normal liver, and 3,284 in MASLD versus MASH. Integrating these results with genome-wide association studies and coexpression networks, we identified two functionally relevant, validated coexpression modules mainly driven by SMOC2, ITGBL1, LOXL1, MGP, SOD3, and TAT, HGD, SLC25A15, respectively, the latter not previously associated with MASLD and MASH. Our findings provide a comprehensive and robust analysis of hepatic gene expression alterations associated with MASLD and MASH and identify novel key drivers of MASLD progression.
Answers are grounded in this paper and cite their sources.
Should not yet change MASLD/MASH practice; extends transcriptomic meta-analyses and highlights candidates for mechanistic validation.
No takes yet. Share an insight, caveat, or question.
Piras et al. (2024) conducted a meta-analysis in Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (n=1,058). Gene expression profiling vs. Normal liver (CTL) and MASLD was evaluated on Differentially expressed genes (DEGs). A comprehensive meta-analysis of 1,058 liver biopsy samples identified 3,284 differentially expressed genes between MASLD and MASH, revealing novel key drivers of disease progression including SMOC2, ITGBL1, and LOXL1.
Synapse has enriched 10 related papers. Consider them for comparative context: